Michael Pacanowski1, Shashi Amur, Issam Zineh. Show Affiliations » 1. Genomics Group, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA. michael.pacanowski@fda.hhs.gov
Abstract
Mesh： See more » Antiviral Agents/pharmacologyAntiviral Agents/therapeutic useDNA, Viral/classificationDNA, Viral/drug effectsGenotypeHepatitis C, Chronic/drug therapyHepatitis C, Chronic/geneticsHumansInterferon-alpha/therapeutic useInterferonsInterleukins/geneticsOligopeptides/therapeutic usePharmacogenetics/trendsPolyethylene Glycols/therapeutic usePolymorphism, Single NucleotidePrecision MedicineProline/analogs & derivativesProline/therapeutic useRecombinant Proteins/therapeutic useRibavirin/therapeutic use
Substances： See more » Antiviral AgentsDNA, ViralIFNL3 protein, humanInterferon-alphaInterleukinsOligopeptidesRecombinant ProteinsPolyethylene GlycolsRibavirintelaprevirN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamideInterferonsProlinepeginterferon alfa-2a
Year: 2012 PMID： 22570460 DOI： 10.1001/jama.2012.3516
Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272